# US 2026/0092054 A1 · Fused ring compound and pharmaceutical containing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092054 A1
- Document ID: US20260092054A1
- Status: Published application
- Kind: A1
- Application number: 19/116,232
- Filed: 2023-09-29
- Published: 2026-04-02
- Earliest claimed: 2022-09-30
- Assignees: Kaken Pharmaceutical Co., Ltd.
- Applicants: Kaken Pharmaceutical Co., Ltd.
- Inventors: Yoshitake SUMIKAWA; Issei AKAHOSHI; Masaya KATO
- Web page: https://patentgrep.com/patent/US20260092054A1

## CPC

- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07D 413/10: linked by a carbon chain containing aromatic rings
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/4245: Oxadiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 209/22: with an aralkyl radical attached to the ring nitrogen atom
- C07D 235/14: Radicals substituted by nitrogen atoms (by nitro radicals C07D235/10)
- C07D 235/18: with aryl radicals directly attached in position 2
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a novel compound that has STAT6 inhibitory activity and is effective for treatment of inflammatory diseases such as atopic dermatitis and for allergic diseases. A compound pharmaceutically acceptable salt thereof expressed by general formula (I) having STAT6 inhibitory activity.

## Claims

### Claim 1

A compound of formula (I):
wherein
X1 is CH, X2 is CH, and X4 is CH;
R1 is an optionally substituted 5-membered heteroaryl group, an optionally substituted 5- to 6-membered non-aromatic heterocyclic group, an optionally substituted pyridonyl group, —C(═O)—NRaRb, or —NRc—C(═O)Rd, wherein Ra, Rb, Rc, and Rd each independently represents a hydrogen atom or a C1-C6 alkyl group;
R2 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group;
or R1 and R2 together with the carbon atoms to which they are attached form an optionally substituted 5- to 6-membered non-aromatic heterocyclic group;
R3 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group;
R4 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C1-C6 haloalkyl group, an optionally substituted C1-C3 alkoxy-C2-C6 alkyl group, an optionally substituted C1-C3 haloalkoxy-C2-C6 alkyl group, or an optionally substituted C3-C6 cycloalkyl-C1-C6 alkyl group;
Q1 is C(═O) or CH2;
Q2 is NH or O;
X3 is N or CR6, wherein R6 is a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C1-C6 alkyl group, an optionally substituted C1-C6 haloalkyl group, an optionally substituted hydroxy-C1-C6 alkyl group, an optionally substituted cyano-C1-C6 alkyl group, an optionally substituted C3-C6 cycloalkyl group, an optionally substituted C1-C6 alkoxy-C1-C6 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, or an optionally substituted phenyl group;
Y1 and Y2 are each independently N or CR7, wherein R7 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group; and
ring A is an optionally substituted phenyl group or an optionally substituted 5- to 6-membered heteroaryl group, wherein the phenyl group or the 5- to 6-membered heteroaryl group are optionally further fused with another ring to form an optionally substituted 8- to 10-membered fused ring;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein, Q1 is C(═O) and Q2 is NH.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein Y1 and Y2 are each independently CH or N.

### Claim 6 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein
(i) Y1 is CH and Y2 is CH;
(ii) Y1 is N and X2 is CH; or
(iii) Y1 is CH and Y2 is N.

### Claim 7 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein ring A is an optionally substituted phenyl group, an optionally substituted pyridinyl group, an optionally substituted pyrazolyl group or an optionally substituted thiadiazolyl group.

### Claim 8 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein ring A is a ring selected from a group consisting of
wherein R3 is a hydrogen atom, a cyano group, a hydroxyl group, an amino group, a methanesulfonylamino group, a sulfonamide group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a hydroxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkoxy-C1-C6 alkyl group, a C1-C6 alkylcarbonyl group, an amino-C1-C6 alkyl group, an N-acetylamino-C1-C6 alkyl group, a C1-C6 alkylcarbamoyl group, an N-methyl-C1-C6 alkylcarbamoyl group, an imidazolyl group, a thiazolyl group, or a —C(═O)NHRe group wherein Re is a C1-C6 alkyl group that is optionally substituted with a cyano group, a C1-C6 alkylcarbonyl group that is optionally substituted with a dimethylamino group, or an optionally substituted 5- to 6-membered heteroaryl group; and
R9 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl group.

### Claim 9 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein ring A is a ring selected from a group consisting of
wherein R3 is a hydrogen atom, a cyano group, a hydroxyl group, an amino group, a methanesulfonylamino group, a sulfonamide group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a hydroxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkoxy-C1-C6 alkyl group, a C1-C6 alkylcarbonyl group, an amino-C1-C6 alkyl group, an N-acetylamino-C1-C6 alkyl group, a C1-C6 alkylcarbamoyl group, an N-methyl-C1-C6 alkylcarbamoyl group, an imidazolyl group, a thiazolyl group, or a —C(═O)NHRe group wherein Re is a C1-C6 alkyl group that is optionally substituted with a cyano group, a C1-C6 alkylcarbonyl group that is optionally substituted with a dimethylamino group, or an optionally substituted 5- to 6-membered heteroaryl group; and
R9 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl group.

### Claim 10 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein ring A is
wherein
R3 is a hydrogen atom, a cyano group, a C1-C6 alkyl group, an imidazolyl group, a thiazolyl group or a —C(═O)—NHRe group;
Re is a hydrogen atom, a C16 alkyl group that is optionally substituted with a cyano group, a C16 alkylcarbonyl group that is optionally substituted with a dimethylamino group, or a ring selected from the group consisting of
wherein
R10 is a hydrogen atom, a C1-C6 alkyl group that is optionally substituted with a cyano group, a C1-C6 alkyl group that is optionally substituted with a C3-C6cycloalkyl group, a C1-C6 alkoxy-C1-C6 alkylcarbonyl group, or a C3-C6 cycloalkyl group;
R11 is a hydrogen atom, a halogen atom, or a cyano group;
R12 is a hydrogen atom or C1-C6 alkyl group;
R13 is a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkyl group that is optionally substituted with a halogen atom;
R14 is a hydrogen atom or a C1-C6 alkyl group; and
R15 is a hydrogen atom, C1-C6 alkyl group, or a C1-C6 alkoxy-C1-C6 alkyl group.

### Claim 11 (depends on 1)

The compound, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein
R1 is a ring selected from a group consisting of
wherein R16 is a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;
or R1 is a —C(═O—NRaRb group or an —NRc—C(═O)Rd group, wherein Rc, Rb, Rc, and Rd are each independently a hydrogen atom or a C1-C6 alkyl group;
or R1 and R2 together with the carbon atoms to which they are attached form a ring having the following structure
wherein
*1 is a carbon atom to which R1 is bonded, and
*2 is a carbon atom to which R2 is bonded.

### Claim 12 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein
R4 is a C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C3 alkoxy-C2-C6 alkyl group, C1-C3 haloalkoxy-C2-C6 alkyl group, or a C3-C6 cycloalkyl-C1-C6 alkyl group that is optionally substituted with a cyano group.

### Claim 13 (depends on 1)

The compound, or pharmaceutically acceptable salt thereof, according to claim 1, wherein
X3 is a CR6 group, wherein R6 is a hydrogen atom, a halogen atom, a cyano group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a hydroxy-C1-C6 alkyl group, a cyano-C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C1-C6 alkoxy-C1-C6 alkyl group, a C1-C6 alkenyl group, a C1-C6 alkynyl group, or a phenyl group.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A medicament comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.

### Claim at position 16

16-18. (canceled)

### Claim 19 (depends on 1)

A method for preventing or treating one or more diseases selected from the group consisting of chronic obstructive pulmonary disease, atopic dermatitis, bronchial asthma, bullous pemphigoid, nasal polyps, chronic rhinosinusitis, allergic rhinitis, eosinophilic esophagitis, prurigo, and urticaria, wherein the method comprises: administering a compound, or pharmaceutically acceptable salt thereof, according to claim 1 to a subject in need thereof.

### Claim 20 (depends on 1)

A method of preventing or treating a disease associated with STAT6, said method comprising administering the compound, or pharmaceutically acceptable salt thereof, according to claim 1 to a subject in need thereof.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

A compound of formula (I):
wherein
X1 is N, X2 is CH, and X4 is CH;
R1 is an optionally substituted 5-membered heteroaryl group, an optionally substituted 5- to 6-membered non-aromatic heterocyclic group, an optionally substituted pyridonyl group, —C(═O)—NRaRb, or —NRc—C(═O)Rd, wherein Ra, Rb, Rc, and Rd each independently represents a hydrogen atom or a C1-C6 alkyl group;
R2 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group;
or R1 and R2 together with the carbon atoms to which they are attached form an optionally substituted 5- to 6-membered non-aromatic heterocyclic group;
R3 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group;
R4 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C1-C6 haloalkyl group, an optionally substituted C1-C3 alkoxy-C2-C6 alkyl group, an optionally substituted C1-C3 haloalkoxy-C2-C6 alkyl group, or an optionally substituted C3-C6 cycloalkyl-C1-C6 alkyl group;
Q1 is C(═O) or CH2;
Q2 is NH or O;
X3 is N or CR6, wherein R6 is a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C1-C6 alkyl group, an optionally substituted C1-C6 haloalkyl group, an optionally substituted hydroxy-C1-C6 alkyl group, an optionally substituted cyano-C1-C6 alkyl group, an optionally substituted C3-C6 cycloalkyl group, an optionally substituted C1-C6 alkoxy-C1-C6 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, or an optionally substituted phenyl group;
Y1 and Y2 are each independently N or CR7, wherein R7 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group; and
ring A is an optionally substituted phenyl group or an optionally substituted 5- to 6-membered heteroaryl group, wherein the phenyl group or the 5- to 6-membered heteroaryl group are optionally further fused with another ring to form an optionally substituted 8- to 10-membered fused ring;
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

A medicament comprising a compound according to claim 23, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.

### Claim 25 (depends on 23)

A method for preventing or treating one or more diseases selected from the group consisting of chronic obstructive pulmonary disease, atopic dermatitis, bronchial asthma, bullous pemphigoid, nasal polyps, chronic rhinosinusitis, allergic rhinitis, eosinophilic esophagitis, prurigo, and urticaria, wherein the method comprises: administering a compound, or pharmaceutically acceptable salt thereof, according to claim 23 to a subject in need thereof.

### Claim 26

A compound of formula (I):
wherein
X1 is CH, X2 is CH, and X4 is N;
R1 is an optionally substituted 5-membered heteroaryl group, an optionally substituted 5- to 6-membered non-aromatic heterocyclic group, an optionally substituted pyridonyl group, —C(═O)—NRaRb, or —NRc—C(═O)Rd, wherein Ra, Rb, Rc, and Rd each independently represents a hydrogen atom or a C1-C6 alkyl group;
R2 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group;
or R1 and R2 together with the carbon atoms to which they are attached form an optionally substituted 5- to 6-membered non-aromatic heterocyclic group;
R3 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group;
R4 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C1-C6 haloalkyl group, an optionally substituted C1-C3 alkoxy-C2-C6 alkyl group, an optionally substituted C1-C3 haloalkoxy-C2-C6 alkyl group, or an optionally substituted C3-C6 cycloalkyl-C1-C6 alkyl group;
Q1 is C(═O) or CH2;
Q2 is NH or O;
X3 is N or CR6, wherein R6 is a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C1-C6 alkyl group, an optionally substituted C1-C6 haloalkyl group, an optionally substituted hydroxy-C1-C6 alkyl group, an optionally substituted cyano-C1-C6 alkyl group, an optionally substituted C3-C6 cycloalkyl group, an optionally substituted C1-C6 alkoxy-C1-C6 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, or an optionally substituted phenyl group;
Y1 and Y2 are each independently N or CR7, wherein R7 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted C1-C6 haloalkyl group; and
ring A is an optionally substituted phenyl group or an optionally substituted 5- to 6-membered heteroaryl group, wherein the phenyl group or the 5- to 6-membered heteroaryl group are optionally further fused with another ring to form an optionally substituted 8- to 10-membered fused ring;
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

A medicament comprising a compound according to claim 26, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.

### Claim 28 (depends on 26)

A method for preventing or treating one or more diseases selected from the group consisting of chronic obstructive pulmonary disease, atopic dermatitis, bronchial asthma, bullous pemphigoid, nasal polyps, chronic rhinosinusitis, allergic rhinitis, eosinophilic esophagitis, prurigo, and urticaria, wherein the method comprises: administering a compound, or pharmaceutically acceptable salt thereof, according to claim 26 to a subject in need thereof.
